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Abstract
The recent Cochrane report on albumin administration is analysed and criticised on the
grounds of clinical methodology, content and interpretation. Although it is naïve and illogical
to treat hypoalbuminaemia with albumin infusions, a more balanced view on the use of
albumin for resuscitation in acute hypovolaemia is necessary. Once the acute phase of
critical illness is past, interstitial volume is often expanded causing oedema, with a low
plasma volume. We argue for the use of salt-poor albumin solutions in this situation and
conclude that, on current evidence, the assertion that albumin should be avoided in all
situations is irrational and untenable.
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Introduction
Meta-analyses and systematic reviews are useful, but
potentially dangerous tools in the present age of evidence-
based medicine. Evidence presented in such studies is
graded as type Ia, and is more than likely to be accepted
uncritically and to change clinical practice. The conduct of
a systematic review or a meta-analysis is, therefore, a
process of utmost scientific importance, and must be
undertaken with the same care as a randomized controlled
study [1]. Any meta-analysis is only as good as the studies
included. Each study needs to be critically appraised and
rated not only for its statistical methodology, but also for
its clinical and physiological validity.
The systematic review of the use of albumin by the
Cochrane Injuries Group [2] has rightly been criticized for
a number of reasons. First, the media hype that accompa-
nied it was inappropriate for a subject that requires ratio-
nal scientific appraisal. Second, pooling data from studies
on extremely heterogeneous groups of patients makes firm
conclusions difficult. Third, although the authors were
undoubtedly expert statisticians, none of them appeared
to have much understanding or experience of the underly-
ing pathophysiological problems being studied. Thus,
although they were able to score the trials analyzed for
their statistical validity, they appeared to take no account
of the clinical and physiological validity of the studies
being conducted. There was no comment, for example, on
whether the fluids studied were titrated to accurate physi-
ological end-points, or were merely given in absolute
amounts, irrespective of the underlying physiology. Solu-
tions of albumin, crystalloids or plasma substitutes cannot
be treated like drugs of fixed dosage, and need to be
titrated to desirable physiological end-points. This is
because if they are given indiscriminately to individuals
with a normal or excessive plasma volume, there are
clearly grave risks of overloading the patient and increas-
ing mortality.
A further major condemnation was the fact that the paper
was published despite adverse referee criticism [3], and a
number of paediatricians and burns specialists criticizedCritical Care    Vol 4 No 3 Allison and Lobo
the inadequacy of the studies quoted from their own fields
[4–6]. It is common practice, for example, to use albumin
in the management of shock associated with meningococ-
cal meningitis in children, and also in the postshock phase
in severe burns. None of the studies in the review were
designed with mortality as the primary end-point, and
there was therefore no prerandomization stratification for
mortality risk. Thus, conclusions concerning mortality can
be only tentative at best.
It was perhaps the messianic rather than scientific method
of its public presentation that antagonized many thoughtful
clinicians. If, instead, its conclusions had been presented
with caution and as a stimulus to further carefully con-
ducted studies in specific groups of patients, then despite
its limitations it would have served a useful purpose.
One might draw an analogy with the situation in the late
1970s and early 1980s concerning nutritional support.
Critics such as Koretz [7] and Detsky et al [8] were rightly
able to point to the lack of clear evidence that nutritional
support was beneficial, and also to the poor quality of many
of the studies conducted up to that point. Since that time, a
whole flood of excellent studies has defined clear benefit in
certain clinical circumstances and in certain groups of
patients. Conversely, they have shown either no benefit or
even harm in other groups. The clinical indications for this
modality of treatment have therefore become much better
defined. In the present discussion we make a plea for a
similarly thoughtful approach to the use of albumin.
Clinical situations
There are three clinical situations in which albumin has
been or should be considered: hypoalbuminaemia; resus-
citation in acute hypovolaemia; and in hypovolaemia
occurring after the acute phase of critical illness.
Hypoalbuminaemia
Use of albumin in hypoalbuminaemia is the ultimate naïveté,
because hypoalbuminaemia bears no direct relationship to
plasma or other fluid compartment volumes. It may occur in
the presence of intravascular overload or deficit; it is also
affected by dilution, disease and distributional factors. We
may therefore dismiss the hypoalbuminaemia group of
studies considered in the Cochrane report [2], because
there must be few, if any, clinicians who would even con-
sider using albumin merely to correct a serum albumin con-
centration. One might just as well say that all patients with
hyponatraemia should be given salt solutions, irrespective
of the patient’s total extracellular sodium.
Resuscitation in acute hypovolaemia
Here again, in the adult patient there is no evidence in
most situations that albumin solutions are any better than
crystalloids or plasma substitutes. Indeed, at face value
the results of the Cochrane report [2] are open to the
interpretation either that there is no difference between
albumin and other solutions, or that albumin gives a worse
outcome, but not that albumin is potentially superior to any
other solutions.
Another systematic review of colloids (including albumin)
versus crystalloids [9] included methodological quality
assessment of 17 trials on 814 patients, with mortality
data. That review rightly concluded that, although the mor-
tality results tended to favour the crystalloid group, an
excess mortality in the colloid group could not be inferred
on statistical analysis. It also suggested that colloids
caused less pulmonary oedema than crystalloids, with a
relative risk (95% confidence interval) of 0.84
(0.25–2.45). That review excluded studies in which hyper-
tonic crystalloids were used in order to avoid the con-
founding influence of these solutions. Trial quality was
assessed by evaluating the randomization procedure, pop-
ulation description, blinding, documentation of cointerven-
tions and whether patient selection was consecutive. On
this basis, only 11 out of the 17 studies had a validity
score of 8 or more (worst possible score 0; best possible
score 16). The authors of that review also assessed the
use of physiological end-points such as tissue perfusion
and oncotic pressure.
It is argued that, during the acute phase of critical illness,
the transcapillary escape rate of albumin is high, and
therefore administered albumin is not retained within the
circulation for a sufficient length of time to be useful, and
may accumulate in the tissues, causing adverse effects.
Even here one should be cautious because there were
some studies quoted in the Cochrane report that mea-
sured the physiological consequences of giving albumin
versus crystalloid solutions, and appeared to show supe-
rior physiological effects of giving albumin without any
detriment in terms of mortality [10,11].
The papers with the largest relative risk of death in the
albumin group [12–14], and which therefore weighted the
meta-analysis of the Cochrane Injuries Group [2], are
either open to major criticism in terms of physiological and
clinical methodology or are so small and with so few
deaths that mortality figures in the studies themselves
were statistically insignificant. The small study by Zetter-
strom [12], with its relative risk of 5.0, had only two deaths
out of 18 in the entire study, both in the albumin group.
The study of Woods and Kelley [13] had only one death in
69 patients, but the relative risk was 2.61. This paper was
included by the Cochrane reviewers in the hypovolaemia
group even though the authors categorically state that
‘thirty-four treatment group patients (n=37) received
albumin for low levels postoperatively’ [13], clearly indicat-
ing that the study should have been analyzed in the
hypoalbuminaemia group. In none of these studies was
mortality cited as a primary or even a secondary end-point.http://ccforum.com/content/4/3/147
The paper with the largest excess mortality, by Lucas et al
[14], showed that this was predominantly due to car-
diopulmonary failure. In that study, albumin was added to a
standardized fluid resuscitation regimen in the protocol
group, rather than being substituted for other fluids. This
meant that the protocol group received higher volumes of
fluids than did the control individuals, and it is hardly sur-
prising therefore that there was an excess mortality in a
group that was clearly given excessive fluid. It is of note
that the albumin group received the same salt load as the
nonalbumin group in phase 1, and a greater than average
salt load in phases 2 and 3 of the resuscitation process.
Patients in the albumin group also received more whole
blood and fresh frozen plasma than did the control individ-
uals. In fact, not unexpectedly, the measured plasma
volume in the albumin group was, on average, 1294ml
greater than the theoretically expected volume.
As Webb [15] recently indicated, most of the papers dis-
cussed in the Cochrane study were designed to assess
the effects of various fluids on physiological variables, and
were not designed to assess mortality. He pointed out that
a randomized controlled trial comparing one colloid with
one crystalloid would require over 6500 patients to detect
an excess mortality from colloid of 4% on the basis of the
data presented in the Cochrane review. He concluded ‘I
cannot see how we can make a meaningful statement on
comparative mortality.’
Although current evidence does not favour the use of
albumin in acute resuscitation in most situations, the
proper scientific view should be that the jury is still out,
particularly in paediatrics. As some have pointed out,
however, the way in which the Cochrane report was pre-
sented and interpreted has made the setting up of careful
trials more rather than less difficult.
It is to be hoped that the recent paper by Sort et al [16]
will be the first of many such trials that will define the indi-
cations for this expensive form of treatment in a more
rational manner. They studied the effect of intravenous
albumin on renal impairment and mortality in patients with
cirrhosis and spontaneous bacterial peritonitis. They ran-
domly assigned 126 patients with cirrhosis and sponta-
neous bacterial peritonitis to treatment with intravenous
cefotaxime (63 patients) or cefotaxime and intravenous
albumin (63 patients). Mortality in the first group was
41%, and 22% in the albumin group. The difference was
significant (P=0.03). The incidence of renal impairment
was also reduced in the albumin group. That study did
not compare the use of albumin with crystalloids or
plasma substitutes. However, because both of these
contain large amounts of sodium, which might be
expected to have adverse effects in cirrhotic persons with
ascites, this is perhaps a theoretical rather than a relevant
clinical consideration.
The contention that albumin should be avoided in acute hypo-
volaemia is therefore a dogmatic and untrue generalization.
Plasma hypovolaemia after the acute phase of critical
illness
One of the problems of resuscitation with crystalloids, or
even the plasma substitutes, which all have a high sodium
content, is that circulatory function is maintained at the
expense of interstitial salt and water overload. The effect
of acute illness and injury on salt and water retention have
been known for many years [17,18]. Acutely ill patients are
unable to excrete an excess salt and water load, and the
return of a sodium diuresis is the first herald of recovery
and convalescence.
One of the major arguments for the use of salt-poor albumin
in resuscitation is that the circulation might be maintained
without incurring a large interstitial salt overload. In the
majority of patients, however, who make a good recovery,
this overload is excreted spontaneously in the postacute
period. Those patients who suffer persisting complications,
however, continue to retain salt and water and to become
increasingly oedematous. We have shown [19], for
example, that patients, who are referred for nutritional
support in the postacute phase and who are oedematous,
have an average salt and water overload equivalent to 10 l
extracellular fluid. This of itself may have adverse effects on
pulmonary and gastrointestinal function. Such patients are
often those with major complications of gastrointestinal
surgery, with dehiscent wounds, intra-abdominal
abscesses, fistulae and continuing losses of serous fluids.
Many of these patients combine interstitial overload with a
low plasma volume, leading to a low renal plasma flow.
These patients are not only unable to diurese their salt and
water overload because of renal responses to plasma hypo-
volaemia, but are also diuretic resistant. The logical treat-
ment of such patients is the use of salt-poor concentrated
albumin in a dose that is titrated carefully to physiological
end-points such as central venous pressure, pulse rate,
blood pressure, and urinary salt and water excretion.
Plasma substitutes contain high sodium concentrations
and have a shorter half-life than plasma or albumin in the
circulation. It seems, therefore, less appropriate to use
these in the postacute phase. Compounding the salt
excess with crystalloid is certainly inappropriate and
merely worsens the oedema. Our own experience of the
use of salt-poor albumin under these circumstances is that
the diuresis ensues immediately with improved cardiovas-
cular parameters. We have also found, in our clinical expe-
rience, that such patients only require 200–400ml of 20%
salt-poor albumin over 48 h. Once the plasma volume has
been restored, no further administration of albumin is nec-
essary, thereby indicating that the albumin is retained
within the circulation, rather than leaking out continuously
as it might do in the acute phase of illness.It is common practice in some burns centres to use
albumin during the postacute phase [6]. Many years ago
we reported data on fluid and electrolyte balance in
burned patients during the weeks after injury, and
described the appropriate use of plasma and whole blood
to sustain the intravascular volume at a level where salt
and water diuresis occurred [20]. The Cochrane report [2]
did not even mention the postacute situation, in which
there are few formal studies. Doctors whose main experi-
ence is in intensive or critical care rarely have to deal with
this postacute problem, and because most of the literature
concerning the use of crystalloid, colloids and albumin
emanates from this group, it is hardly surprising that it has
received little or no attention, despite the fact that it is an
important and common clinical entity. Studies comparing
salt-poor albumin and plasma substitutes, titrated to physi-
ological end-points, are needed in this situation.
Conclusion
We make a plea for a more thoughtful approach to the
therapeutic use of albumin solutions.
There is no physiological logic in using albumin simply for
hypoalbuminaemia, because it is plasma volume rather
than protein concentration that is most clinically relevant.
In acute resuscitation, we accept that the weight of litera-
ture suggests at least that albumin has no advantage over
crystalloid or other colloids in most cases, although there
may be specific instances in adults and in children where
its use may be beneficial, and one recent paper [16] con-
cerning its use in peritonitis in cirrhotic persons showed a
clear reduction in mortality. To regard this subject as
closed by the Cochrane report would be unfortunate in
the extreme, and we express the hope that further careful
studies will be published in this area.
Finally, during the postacute phase of major illness, there
are many patients who are left with an interstitial salt and
water overload combined with a low plasma volume, in
which the use of concentrated salt-poor albumin is the
most logical treatment. Although clinical experience with
the use of albumin in this group of patients is encouraging,
formal studies are required to compare the use of albumin
with that of the less expensive plasma substitutes.
The question to be addressed in each clinical situation is
not only whether albumin is better than other fluids, but
whether cheaper substitutes are just as effective and,
therefore, more cost effective. We plead for an open-
minded, thoughtful and scientific approach to this field,
devoid of hyperbole or messianic fervour. We suggest that
the view that albumin administration should be avoided in
all situations is, on current evidence, untenable.
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